Purpose: Therapeutic drug monitoring (TDM) is a well-established tool for guiding psychopharmacotherapy and improving patient care. Despite their established roles in the prescription of psychotropic drugs, the "behind the curtain" processes of TDM requests are invariably obscure to clinicians, and literature addressing this topic is scarce.
Methods: In the present narrative review, we provide a comprehensive overview of the various steps, starting from requesting TDM to interpreting TDM findings, in routine clinical practice. Our goal was to improve clinicians' insights into the numerous factors that may explain the variations in TDM findings due to methodological issues.
Results: We discussed challenges throughout the TDM process, starting from the analyte and its major variation forms, through sampling procedures and pre-analytical conditions, time of blood sampling, sample matrices, and collection tubes, to analytical methods, their advantages and shortcomings, and the applied quality procedures. Additionally, we critically reviewed the current and future advances in the TDM of psychotropic drugs.
Conclusions: The "behind the curtain" processes enabling TDM involve a multidisciplinary team, which faces numerous challenges in clinical routine. A better understanding of these processes will allow clinicians to join the efforts for achieving higher-quality TDM findings, which will in turn improve treatment effectiveness and safety outcomes of psychotropic agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/FTD.0000000000001092 | DOI Listing |
Front Med (Lausanne)
December 2024
Department of Pharmacy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China.
Background: Due to its potent antibacterial activity, vancomycin is widely used in the treatment of sepsis. Therapeutic drug monitoring (TDM) can optimize personalized vancomycin dosing regimens, enhancing therapeutic efficacy and minimizing nephrotoxic risk, thereby potentially improving patient outcomes. However, it remains uncertain whether TDM affects the mortality rate among sepsis patients or whether age plays a role in this outcome.
View Article and Find Full Text PDFBMC Med Educ
December 2024
Pontificia Universidad Catolica de Chile, Vicuña Mackenna, Macul, Santiago, Chile.
Background: Therapy decision-making (TDM) is an essential medical skill. However, teaching therapeutic reasoning poses significant challenges. We present a comprehensive TDM course for medical students and report on student satisfaction with the educational strategies, their perceived importance of various TDM domains, and their self-efficacy in incorporating these elements into clinical decisions.
View Article and Find Full Text PDFSci Rep
December 2024
Spectroscopy Department, National Research Centre, 33 El-Bohouth St., Dokki, Giza, 12622, Egypt.
One of the biggest challenges in food packaging is the creation of sustainable and eco-friendly packaging materials to shield foods from ultraviolet (UV) photochemical damage and to preserve the distinctive physical, chemical, and biological characteristics of foods throughout the supply chain. Accordingly, this study focuses on enhancing the UV shielding properties and biological activity of carboxylmethyl cellulose sodium (CMC) through modifications using zinc oxide (ZnO), copper oxide (CuO), and graphene oxide (GO) using the solution casting technique. The hybrid nanocomposites were characterized by fourier-transform infrared (FTIR) spectrophotometer, ultraviolet-visible (UV-Vis) spectrophotometer, scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), and x-ray diffraction (XRD).
View Article and Find Full Text PDFJ Affect Disord
December 2024
Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression.
Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with psychological support.
Pharmacogenomics
December 2024
Department of Pharmacy, Radboudumc Research Institute for medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Dolutegravir (DTG) is an antiviral agent used for the treatment of HIV, however, there is uncertainty over the influence of genetic variation on DTG exposure, and whether it has clinical implications for the efficacy or toxicity in different populations. This systematic review aims to create an overview of the impact of pharmacogenomics (PGx) on DTG exposure, efficacy, and toxicity.
Methods: Publications up to 14 November 2023 were searched and articles were selected on the following criteria: original research articles providing data on people with HIV, data on PGx and either PK or PD or both PD and PGx.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!